Provided by Tiger Trade Technology Pte. Ltd.

Merck

143.81
-1.5000-1.03%
Post-market: 144.000.1900+0.13%18:37 EDT
Volume:7.86M
Turnover:1.13B
Market Cap:354.80B
PE:112.98
High:145.39
Open:144.71
Low:143.26
Close:145.31
52wk High:156.92
52wk Low:82.01
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.88
T/O Rate:0.32%
Dividend:3.32
Dividend Rate:2.31%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.46
PE(LYR):19.75

Loading ...

Merck & Co. Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
2 hours ago

Merck's Tulisokibart Data From Hidradenitis Suppurativa Trial Looks Solid, UBS Securities Says

MT Newswires Live
·
6 hours ago

Jefferies Adjusts Price Target on Merck & Co to $177 From $175, Keeps Buy Rating

MT Newswires Live
·
Yesterday

Merck Schedules Third-Quarter Sales and Earnings Conference Call with Investors and Analysts

Reuters
·
Yesterday

Merck & Co Inc : Jefferies Raises Target Price to $177 from $175

THOMSON REUTERS
·
Yesterday

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Yesterday

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Yesterday

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Yesterday

Dow Drops 150 Points on Losses for Shares of Sherwin-Williams Co., Merck

Dow Jones
·
Yesterday

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30

Merck & Co - no Serious or Opportunistic Infections Observed in Study

THOMSON REUTERS
·
Sep 30

Marka S.A. Pays Twelfth Installment Under Amended Bondholder Arrangement

TIPRANKS
·
Sep 30

US Drug Lobby Group PhRMA Names Former House Leader Cantor as CEO

Reuters
·
Sep 30

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 29